Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Adaptive Biotechnologies
Adaptive Announces Launch of Epic Integration for clonoSEQ®
September 13, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 30, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
August 02, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023
July 10, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
June 02, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
May 24, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
May 12, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
May 09, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
May 03, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference
April 25, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
April 12, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
April 06, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference
February 27, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results
February 14, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
January 23, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 27, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
December 10, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting
December 05, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
December 01, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
November 21, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results
November 21, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
October 11, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022
October 05, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.